Syqe® Medical is conducting a unique clinical study simultaneously at 50 medical centers worldwide, including in Israel, Europe, and Australia. The study is examining an innovative technology that will be an additional treatment for diabetic neuropathic pain: medical cannabis (in the aerosol) administered by inhalation using the Syqe® Fixed Dose Inhaler.
The study will evaluate the efficacy, safety, tolerability, and pharmacokinetics (the body’s effect on substances introduced into it, such as drugs) of inhaled THC at metered doses of 0.25 mg, 0.5 mg, and 1 mg – administered via the Syqe® Inhaler three times a day for 22 weeks, compared to placebo. The TGA* (Therapeutic Goods Administration)-approved device allows patients to receive a metered dose of full-spectrum THC (in the aerosol) in a standardized manner. Researchers aim to identify changes in pain characteristics, along with changes in sleep, quality of life, and general well-being. Preparations are currently underway to screen Australian participants for the study.
Read the full article>>
*The regulatory body in the field of medical devices in Australia.
